Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

BACKGROUND: Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). We hypothesized that circulating tumor c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Tamminga, Menno, de Wit, Sanne, Hiltermann, T. Jeroen N., Timens, Wim, Schuuring, Ed, Terstappen, Leon W. M. M., Groen, Harry J. M.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617698/
https://ncbi.nlm.nih.gov/pubmed/31291995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0649-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados